As Biotechnology businesses, Aptinyx Inc. (NASDAQ:APTX) and BeiGene Ltd. (NASDAQ:BGNE), are affected by contrast. This especially applies to their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptinyx Inc. 6.72M 20.54 46.41M -1.42 0.00 BeiGene Ltd. 198.22M 40.91 673.77M -9.61 0.00 Demonstrates Aptinyx Inc. and BeiGene Ltd. earnings per share, top-line revenue and valuation.
Table 2 represents Aptinyx Inc. (NASDAQ:APTX) and BeiGene Ltd. (NASDAQ:BGNE)’s return on assets, net margins and return on equity. BeiGene Ltd. -339.91% -18.7% -14.3% Liquidity
The Current Ratio of Aptinyx Inc. is 21.8 while its Quick Ratio stands at 21.8. The Current Ratio of rival BeiGene Ltd. is 11.6 and its Quick Ratio is has 11.5. Aptinyx Inc. is better equipped to clear short and long-term obligations than BeiGene Ltd.
Insider and Institutional Ownership
The shares of both Aptinyx Inc. and BeiGene Ltd. are owned by institutional investors at 74.6% and 80.7% respectively. Insiders held roughly 2.8% of Aptinyx Inc.’s shares. Competitively, insiders own roughly 0.03% of BeiGene Ltd.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Aptinyx Inc. -9.41% 0.94% -76.28% -76.78% 0% -67.41% BeiGene Ltd. 8.88% 17.26% 1.55% -15.13% 5.64% 8.25% For the past year Aptinyx Inc. has -67.41% weaker performance while BeiGene Ltd. has 8.25% stronger performance.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to develop and commercialize BeiGene, Ltd.Â’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317. BeiGene, Ltd. was founded in 2010 and is based in Camana Bay, Cayman Islands.
Click here to view original web page at Reviewing Aptinyx Inc. (APTX)’s and BeiGene Ltd. (NASDAQ:BGNE)’s results